In the May 15, 2001, issue of BioWorld Today the annual worldwide sales of Johnson & Johnson¿s Procrit should have been reported as about $2 billion, not $1.2 billion. J& J¿s oncology-related anemia sales of Procrit are about $1.2 billion, Roth Capital Partners Inc.¿s Fariba Ghodsian said.

Editor¿s note: The error has been corrected in BioWorld Online.